Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Martin Bødtker, Mortensen"'
Autor:
Roni Ranghoej Nielsen, Kasper Pryds, Kevin Kris Warnakula Olesen, Martin Bødtker Mortensen, Christine Gyldenkerne, Jens Cosedis Nielsen, Gerhard Hindricks, Nikolaos Dagres, Michael Maeng
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 14 (2024)
Background In patients with newly diagnosed heart failure (HF) and left ventricular ejection fraction (LVEF)
Externí odkaz:
https://doaj.org/article/8bf999e7b6b745618c6c1dcccc9b8bfa
Autor:
Frederik Pagh Bredahl Kristensen, Diana Hedevang Christensen, Martin Bødtker Mortensen, Michael Maeng, Johnny Kahlert, Henrik Toft Sørensen, Reimar Wernich Thomsen
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background Elevated triglyceride levels are a clinically useful marker of remnant cholesterol. It is unknown whether triglycerides are associated with residual cardiovascular risk in CVD-naïve patients with newly diagnosed type 2 diabetes m
Externí odkaz:
https://doaj.org/article/fbed8e08e4e54c31a8c86d1b277dbe27
Autor:
Peter P. Toth, Jean Ferrières, Max Waters, Martin Bødtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and addition
Externí odkaz:
https://doaj.org/article/addedc3ef14445b8864bc454821eac33
Autor:
Emili Vela, Montse Cleries, Usama Bilal, Maciej Banach, John W McEvoy, Martin Bødtker Mortensen, Michael Joseph Blaha, Khurram Nasir, Josep Comin-Colet, Josepa Mauri, Miguel Cainzos-Achirica
Publikováno v:
Archives of Medical Science, Vol 19, Iss 1, Pp 35-45 (2021)
Introduction The ESC recently classified European countries into 4 cardiovascular risk regions. However, whether Europeans from higher-risk countries living in lower-risk regions may benefit from intensive cardiovascular prevention efforts is unknown
Externí odkaz:
https://doaj.org/article/99707d9e3f834f8c9a3b34a3545f7b16
Autor:
Omar Dzaye, Philipp Berning, Alexander C. Razavi, Rishav Adhikari, Kunal Jha, Khurram Nasir, John W. Ayers, Martin Bødtker Mortensen, Michael J. Blaha
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent rep
Externí odkaz:
https://doaj.org/article/b72e5ce680664ce39f6bccbdec26c84c
Autor:
Omar Dzaye, MD, PhD, Philipp Berning, MD, Siegfried Adelhoefer, Matthias Duebgen, MD, Ron Blankstein, MD, Mahadevappa Mahesh, MS, PhD, Khurram Nasir, MD, MPH, MSc, Roger S. Blumenthal, MD, Martin Bødtker Mortensen, MD, PhD, Michael J. Blaha, MD, MPH
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 456-465 (2021)
Objective: To evaluate interest in coronary artery calcium (CAC) among the general public during the past 17 years and to compare trends with real-world data on number of CAC procedures performed. Methods: We used Google Trends, a publicly available
Externí odkaz:
https://doaj.org/article/5929d4e4c86a496392b1eb93da1b5043
Autor:
Martin Bødtker Mortensen, Omar Dzaye, Hans Erik Bøtker, Jesper Møller Jensen, Michael Maeng, Jacob Fog Bentzon, Helle Kanstrup, Henrik Toft Sørensen, Jonathon Leipsic, Ron Blankstein, Khurram Nasir, Michael J. Blaha, Bjarne Linde Nørgaard
Publikováno v:
Mortensen, M B, Dzaye, O, Bøtker, H E, Jensen, J M, Maeng, M, Bentzen, J F, Kanstrup, H, Sørensen, H T, Leipsic, J, Blankstein, R, Nasir, K, Blaha, M J & Nørgaard, B L 2023, ' Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis : The Western Denmark Heart Registry ', Circulation, vol. 147, no. 14, pp. 1053-1063 . https://doi.org/10.1161/CIRCULATIONAHA.122.061010
Background: Low-density lipoprotein cholesterol (LDL-C) is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, a sizable proportion of middle-aged individuals with elevated LDL-C level have not developed coron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f00fc5c36407f50004fae2d3bb1592fe
https://doi.org/10.1161/circulationaha.122.061010
https://doi.org/10.1161/circulationaha.122.061010
Publikováno v:
Preventive Medicine Reports, Vol 6, Iss C, Pp 182-186 (2017)
Preventive therapy in primary care is guided by risk thresholds for future cardiovascular events. We aimed to assess whether the sensitivity of various risk calculators for the detection of subclinical carotid atherosclerosis (TPA80) could be improve
Externí odkaz:
https://doaj.org/article/f3cb0b12753648ab8777a5aef42f9c57
Autor:
Alexander C. Razavi, S.M. Iftekhar Uddin, Zeina A. Dardari, Daniel S. Berman, Matthew J. Budoff, Michael D. Miedema, Albert D. Osei, Olufunmilayo H. Obisesan, Khurram Nasir, Alan Rozanski, John A. Rumberger, Leslee J. Shaw, Laurence S. Sperling, Seamus P. Whelton, Martin Bødtker Mortensen, Michael J. Blaha, Omar Dzaye
Publikováno v:
JACC: Cardiovascular Imaging. 15:1259-1270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a37b7661ddf2e4e0fe8937cc121f50
https://doi.org/10.1016/j.jcmg.2022.02.011
https://doi.org/10.1016/j.jcmg.2022.02.011
Autor:
Thomas Jensen, Pernille G Thrane, Kevin K W Olesen, Morten Würtz, Martin Bødtker Mortensen, Christine Gyldenkerne, Troels Thim, Bjarne Linde Nørgaard, Jesper Møller Jensen, Steen Dalby Kristensen, Jens C Nielsen, John W Eikelboom, Michael Maeng
Publikováno v:
Jensen, T, Thrane, P G, Olesen, K K W, Würtz, M, Mortensen, M B, Gyldenkerne, C, Thim, T, Nørgaard, B L, Jensen, J M, Kristensen, S D, Nielsen, J C, Eikelboom, J W & Maeng, M 2023, ' Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 3, 208-219 . https://doi.org/10.1093/ehjcvp/pvac058
Aims Beyond 1 year after percutaneous coronary intervention (PCI), guidelines recommend anticoagulant monotherapy in patients with atrial fibrillation (AF) rather than dual therapy with an anticoagulant and an antiplatelet drug. The risks and benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7add3fd87c25fefd581498b0774066c2
https://pure.au.dk/portal/da/publications/antithrombotic-treatment-beyond-1-year-after-percutaneous-coronary-intervention-in-patients-with-atrial-fibrillation(9eb5a09e-3167-42a4-abfa-095dd6fb12e6).html
https://pure.au.dk/portal/da/publications/antithrombotic-treatment-beyond-1-year-after-percutaneous-coronary-intervention-in-patients-with-atrial-fibrillation(9eb5a09e-3167-42a4-abfa-095dd6fb12e6).html
